CU2 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueCerus’s business model centers on single-use consumables required each treatment, creating a recurring, procedure-tied revenue base. This leads to predictable replacement demand, high customer switching costs and stable unit economics that support multi-quarter revenue visibility and margin leverage as volumes scale.
Strong Revenue Growth & Commercial TractionSustained double-digit product growth, raised guidance, and rapid IFC expansion reflect durable market penetration and adoption. Growth driven by platelet kit volumes, BCA purchasing benefits, and EMEA expansion suggests a structural increase in addressable procedure volumes and multi-quarter revenue runway.
Sustained Adjusted EBITDA PositivityEight straight quarters of positive adjusted EBITDA indicate ongoing operating discipline and improving unit economics. Persistent underlying profitability before nonrecurring items supports debt servicing capacity, reinvestment potential, and a credible structural path toward GAAP profitability if revenue and margin trends continue.
Bears Say
Elevated Leverage (debt > Equity)Debt exceeding equity constrains strategic flexibility and increases refinancing and covenant risk until earnings and cash flow sustainably improve. High leverage amplifies downside vulnerability to operational setbacks or delayed regulatory milestones over the next several quarters.
Volatile Cash Flow And Weak Free Cash FlowInconsistent conversion of earnings to cash and recent negative FCF limit the company’s ability to self-fund growth, reduce leverage, or absorb timing delays from lumpy rollouts. Working-capital-driven cash use highlights structural sensitivity to inventory and shipment timing risks.
Gross Margin Compression And Cost PressuresMaterial margin decline reduces operating leverage from revenue growth and lengthens the timeline to GAAP profitability. Persistent shipping, tariff and FX pressures are structural headwinds that must be offset by pricing, cost reduction, or productivity gains to sustain durable profit improvement.
Cerus News
CU2 FAQ
What was Cerus Corporation’s price range in the past 12 months?
Currently, no data Available
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is CHF350.44M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Oct 29, 2026 which is in 86 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Jul 30, 2026. The company reported -$0.008 earnings per share for the quarter, beating the consensus estimate of -$0.011 by $0.002.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 201,524,900 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.008 in its last earnings report, beating expectations of -$0.011. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CH:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF4.04 (― Upside)
CHF4.04 (― Upside)
Blogger Sentiment
Bullish
CH:CU2 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth CHF43.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.View all CH:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
―Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―